Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.70
-0.13 (-1.90%)
At close: Nov 17, 2025, 4:00 PM EST
6.57
-0.13 (-1.94%)
After-hours: Nov 17, 2025, 7:45 PM EST
Silence Therapeutics Employees
Silence Therapeutics had 116 employees as of December 31, 2024. The number of employees increased by 7 or 6.42% compared to the previous year.
Employees
116
Change (1Y)
7
Growth (1Y)
6.42%
Revenue / Employee
$222,672
Profits / Employee
-$556,379
Market Cap
316.47M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 116 | 7 | 6.42% |
| Dec 31, 2023 | 109 | -13 | -10.66% |
| Dec 31, 2022 | 122 | 17 | 16.19% |
| Dec 31, 2021 | 105 | 40 | 61.54% |
| Dec 31, 2020 | 65 | 19 | 41.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLN News
- 5 days ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 11 days ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 25 days ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 2 months ago - Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 3 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire
- 6 months ago - Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire